Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Microbot Medical Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-05-16).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- H.C. Wainwright & Co., LLC
- Effective
- 2023-05-16
Exact text from the filing
On May 16, 2023 and in connection with the Offerings, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Microbot Medical Inc. entered into Purchase Agreements with institutional investors valued at approximately $1.5 million (effective 2023-06-02).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- institutional investors
- Value
- approximately $1.5 million
- Effective
- 2023-06-02
Exact text from the filing
On June 2, 2023, Microbot Medical Inc., a Delaware corporation (the “Company”), entered into Securities Purchase Agreements (the “Purchase Agreements”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “Registered Offering”), an aggregate of 701,756 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at an offering price of $2.1375 per share, for aggregate gross proceeds from the Offerings (as defined below) of approximately $1.5 million before deducting the placement agent fee (as described in greater detail below) and related offering expenses.
View on SEC.gov